CHPA Speaks During FDA Meeting for Differin® Gel Switch Application

Senior Vice President, Policy, and General Counsel & Secretary David Spangler underscores value of Rx-to-OTC switches to U.S. healthcare system



Washington, D.C. (April 15, 2016) –  The Consumer Healthcare Products Association (CHPA) spoke today before a Food and Drug Administration Advisory Nonprescription Drugs Advisory Committee, during which the committee discussed data submitted by Galderma Laboratories, L.P. to support the supplemental new drug application for over-the-counter (OTC) marketing of adapalene gel 0.1%. The proposed OTC use is for the treatment of acne and to clear up acne pimples and acne blemishes.

CHPA Senior Vice President, Policy, and General Counsel & Secretary David Spangler spoke on behalf of CHPA, highlighting how the power of access through prescription-to-OTC switch benefits consumers and the healthcare system.

Spangler’s presentation is available online.


The Consumer Healthcare Products Association (CHPA) is the 135-year-old national trade association representing the leading manufacturers and marketers of over-the-counter (OTC) medicines and dietary supplements. Every dollar spent by consumers on OTC medicines saves the U.S. healthcare system $6-$7, contributing a total of $102 billion in savings each year. CHPA is committed to empowering consumer self-care by preserving and expanding choice and availability of consumer healthcare products. 

chpa.org

Contact: Jenni Roberson 202.429.9260